dc.contributor
Institut Català de la Salut
dc.contributor
[Agarwal N] Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA. [Saad F] University of Montréal Hospital Center, Montréal, Québec, Canada. [Azad AA] Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. [Mateo J] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Matsubara N] National Cancer Center Hospital East, Chiba, Japan. [Shore ND] Carolina Urologic Research Center, Myrtle Beach, SC, USA
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Matsubara, Nobuaki
dc.contributor.author
Agarwal, Neeraj
dc.contributor.author
Saad, Fred
dc.contributor.author
Azad, Arun
dc.contributor.author
Shore, Neal
dc.contributor.author
Mateo, Joaquin
dc.date.issued
2024-03-27T08:57:30Z
dc.date.issued
2024-03-27T08:57:30Z
dc.date.issued
2023-10-26
dc.identifier
Agarwal N, Saad F, Azad AA, Mateo J, Matsubara N, Shore ND, et al. TALAPRO-3 clinical trial protocol: phase III study of talazoparib plus enzalutamide in metastatic castration-sensitive prostate cancer. Futur Oncol. 2023 Oct 26;20(9):493–505.
dc.identifier
https://hdl.handle.net/11351/11252
dc.identifier
10.2217/fon-2023-0526
dc.identifier
001087207700001
dc.description.abstract
PARP inhibitor; Androgen receptor; Enzalutamide
dc.description.abstract
Inhibidor de PARP; Receptor de andrógenos; Enzalutamida
dc.description.abstract
Inhibidor de PARP; Receptor d'andrògens; Enzalutamida
dc.description.abstract
Poly(ADP-ribose) polymerase inhibitors in combination with androgen-receptor signaling inhibitors are a promising therapeutic option for patients with metastatic castration-sensitive prostate cancer (mCSPC) and homologous recombination repair (HRR) gene alterations. Here, we describe the design and rationale of the multinational, phase III, TALAPRO-3 study comparing talazoparib plus enzalutamide versus placebo plus enzalutamide in patients with mCSPC and HRR gene alterations. The primary end point is investigator-assessed radiographic progression-free survival (rPFS) per RECIST 1.1 in soft tissue, or per PCWG3 criteria in bone. The TALAPRO-3 study will demonstrate whether the addition of talazoparib can improve the efficacy of enzalutamide as assessed by rPFS in patients with mCSPC and HRR gene alterations undergoing androgen deprivation therapy.
Clinical Trial Registration:NCT04821622 (ClinicalTrials.gov)
Registry Name: Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC.
Date of Registration: 29 March 2021.
dc.description.abstract
This study was sponsored by Pfizer. Astellas Pharma Inc. provided enzalutamide.
dc.format
application/pdf
dc.publisher
Future Medicine
dc.relation
Future Oncology;20(9)
dc.relation
https://doi.org/10.2217/fon-2023-0526
dc.rights
Attribution-NonCommercial-NoDerivatives 4.0 International
dc.rights
http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Pròstata - Càncer - Tractament
dc.subject
Antiandrògens - Receptors
dc.subject
DISEASES::Neoplasms::Neoplasms by Site::Urogenital Neoplasms::Genital Neoplasms, Male::Prostatic Neoplasms
dc.subject
CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Physiological Effects of Drugs::Hormones, Hormone Substitutes, and Hormone Antagonists::Hormone Antagonists::Androgen Antagonists::Androgen Receptor Antagonists
dc.subject
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols
dc.subject
DISEASES::Neoplasms::Neoplastic Processes::Neoplasm Metastasis
dc.subject
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias urogenitales::neoplasias de los genitales masculinos::neoplasias de la próstata
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::efectos fisiológicos de los fármacos::hormonas, sustitutos de hormonas y antagonistas de hormonas::antagonistas de hormonas::antagonistas de andrógenos::antagonistas de receptores de andrógenos
dc.subject
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada
dc.subject
ENFERMEDADES::neoplasias::procesos neoplásicos::metástasis neoplásica
dc.title
TALAPRO-3 clinical trial protocol: phase III study of talazoparib plus enzalutamide in metastatic castration-sensitive prostate cancer
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
